Edgewise Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Edgewise Therapeutics Inc 's ROA in the third quarter of 2026?
Edgewise Therapeutics inc achieved a return on average assets (ROA) of 120.84 % in its third quarter of 2026, this is above EWTX's average return on assets of -25.68%.
Edgewise Therapeutics Inc assets over the 12 months ending in its third quarter of 2026 are valued at $835 million

ROA has improved compared to -36.92% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 468 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3675, from total ROA ranking in the second quarter of 2026 at 4310.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	207.06 %	-20.53 %	13.88 %	13.42 %	13.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	1,010	-197	-176	-168	-157
Return On Assets (TTM)	120.84 %	-36.92 %	-31.12 %	-30.52 %	-29.47 %
EWTX's Total Ranking	# 3675	# 4310	# 3778	# 3790	# 3867
Total Assets (TTM) in million	1,787	486	517	551	582
Seq. Total Assets Change	267.54 %	-5.98 %	-6.17 %	-5.29 %	-4.87 %
Seq. Net Income Change	-	-	-	-	-

EWTX's 5 Years Annual ROA >> Back to EWTX Management Effectiveness >> Compare EWTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 185
Sector	# 469
Overall	# 3736

Return On Assets Statistics
High	Average	Low
-14.34 %	-25.68 %	-36.96 %
(Dec 31 2021)		(Jun 30 2026)

Financial Statements
Edgewise Therapeutics Inc 's Assets	$ 1,787 million	EWTX's Balance sheet
Edgewise Therapeutics Inc 's Income	$ 1,166 million	Quarterly EWTX's Income Statement
EWTX's Income by Division		See EWTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	13.42 %	43.17 %	-7.53 %	28.7 %	-
Total Assets in million	551	486	339	367	285
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-168	-134	-100	-68	-43
Annual Return On Assets	-30.44 %	-27.53 %	-29.51 %	-18.43 %	-15.01 %

EWTX's 5 Years Annual ROA >> Back to EWTX Management Effectiveness >> Compare EWTX ROA to its Competitors

More Return On Assets Ratios
EWTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EWTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EWTX's Competitors
Subscribers only: Roa for Edgewise Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for EWTX's Customers

You may also want to know
EWTX's Roi	EWTX's Inventory Turnover Ratio	EWTX's Growth Rates	EWTX's Dividend Comparisons
	EWTX's Profitability Ratios	EWTX's Asset Turnover Ratio	EWTX's Dividend Growth
EWTX's Roe	EWTX's Valuation Ratios	EWTX's Financial Strength Ratios	EWTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Vor Biopharma Inc	277.94 %
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %

Date modified: 2026-11-05T10:30:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.